AUG 7·SEC EDGARLow
ARMEN GARO H purchased $1K of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 5,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.26 on 2026-08-05.
StockOTC · US · USDHealthcare · Biotechnology
$PTIX
Protagenic Therapeutics, Inc.\new
Price · $PTIXvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Top stories · $PTIXMore →
AUG 4·investing.com
Monday’s insider activity: Notable buys and sells disclosed
Investing.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.
AUG 3·SEC EDGAR
ARMEN GARO H purchased $5K of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF.) purchased 26,291 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.18 on 2026-07-30.
PTIX sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning PTIX (Protagenic Therapeutics, Inc.\new). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PTIX coverage spans financial news, insider activity and technology.
In the last 30 days, PTIX insiders filed 2 SEC Form 4 transactions — 2 purchases ($6K) and no sales. The most active reporter was ARMEN GARO H, EXEC. CHAIR & PRINCIPAL OFF., with 1 filing.
What's driving PTIX
The Form 4 shows a small, non-10b5-1 insider buy, which can be sentiment-supportive but is unlikely to change fundamentals on its own.
A large insider buy at depressed levels may be interpreted as confidence, but the company’s valuation context remains the key driver.
The filing is a small, routine insider buy with no stated catalyst or guidance change, so it is unlikely to drive a major repricing by itself.
The article’s actionable new facts are the secured financing and the expected Phase 3 milestones (first patient in H2 2026, partnering window H1 2027).
Positive clinical milestone news triggered a sharp intraday surge; near-term upside is likely but the move may be volatile and may not extend without additional data.
alphai scores every news story that mentions PTIX with an AI model for sentiment and relevance, and aggregates insider trades from Protagenic Therapeutics, Inc.\new's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PTIX
Score
ARMEN GARO H purchased $1K of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 5,000 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.26 on 2026-08-05.
2 min readMonday’s insider activity: Notable buys and sells disclosed
Investing.com reported Monday’s SEC Form 4 insider trades for several US-listed firms. Buys included Hanover Bancorp (HNVR) President Kevin O’Connor buying 10,000 shares at $26.88, Protagenic Therapeutics (PTIX) executive chair buying 26,291 shares at $0.1828, and V F Corp (VFC) CEO buying 32,894 shares at ~$14.98. Sales included Snowflake (SNOW) EVP selling 29,986 shares at $300 and Cactus (WHD) leaders selling 86,700 shares each at $57.618.
7 min readARMEN GARO H purchased $5K of PTIX
ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF.) purchased 26,291 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.18 on 2026-07-30.
1 min readOriginal-Research: Pentixapharm Holding AG (von NuWays AG): BUY
^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
4 min read
Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress - Protagenic Therapeutics (NASDAQ:PTIX)
Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the company announced a key clinical milestone. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
2 min read
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders - Inozyme Pharma (NASDAQ:INZY), Protagenic Therapeutics (NASDAQ:PTIX)
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inozyme Pharma, Inc.
2 min readBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq - INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq - PTIX)
BALA CYNWYD, Pa., May 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
3 min readGold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher - Archer Aviation (NYSE:ACHR), DigiAsia (NASDAQ:FAAS)
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. The Dow traded up 0.40% to 42,825.71 while the NASDAQ rose 0.02% to 19,215.06. The S&P 500 also rose, gaining, 0.13% to 5,965.84. Consumer staples shares rose by 0.1% on Monday.
3 min read
Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger - Protagenic Therapeutics (NASDAQ:PTIX)
Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve ...
2 min readBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq - INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq - PTIX)
BALA CYNWYD, Pa., May 19, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
3 min read